ESMO 2019 — Atezolizumab monotherapy is a promising first-line treatment in PD-L1–selected NSCLC


  • Cristina Ferrario — Agenzia Zoe
  • Oncology Conference reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Compared to platinum-based chemotherapy, monotherapy with atezolizumab improved overall survival (OS) in patients with Wild Type (WT; EGFR/ALK-negative), higher tumour-infiltrating immune cells (IC3) or tumour cells (TC3) metastatic non-small cell lung cancer (mNSCLC).
  • No new or unexpected safety signals.

Why this matters

  • Tumour PD-L1 level and tumour histology are now used to determine treatment regimens in mNSCLC.
  • PD-L1/PD-1 inhibitor (CPI) monotherapy remains an attractive choice for patients ineligible for the immuno-chemotherapy combination.

Study design

  • 572 chemo-naïve patients with stage IV nonsquamous (nsq) or squamous (sq) NSCLC were enrolled in phase 3 IMpower110 study.
  • Patients received atezolizumab 1200 mg intravenous (IV) q3w (Arm A) or platinum-based chemo (Arm B; 4 to 6 21-day cycles).
  • Chemotherapy was cisplatin/carboplatin + pemetrexed for nsq patients and cisplatin/carboplatin + gemcitabine for sq patients.
  • Primary endpoint: OS.
  • Key secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR). 
  • Funding: F. Hoffmann-La Roche.

Key results

  • The 3 primary efficacy populations included 554, 328, and 205 patients with TC1/2/3 or IC1/2/3 WT, TC2/3 or IC2/3 WT and 205 TC3 or IC3 WT disease, respectively.
  • In the TC3 or IC3 WT population, atezolizumab monotherapy improved median OS by 7.1 months (HR 0.595; P=0.0106) vs chemotherapy.
  • In the same population, atezolizumab also showed meaningful improvements in PFS, ORR, and DOR vs chemotherapy.
  • Treatment-related AEs (TRAEs) occurred in 60.5% of patients in atezolizumab group and 85.2% in the chemotherapy group.

Expert commentary

  • “Atezolizumab in IC3/TC3 first-line NSCLC could represent a new standard of care in addition to pembrolizumab in PD-L1 positive tumours,” said Naiyer Rizvi, Director of Thoracic Oncology and Immunotherapeutics, Columbia University Medical Center, New York, USA, who was not involved in the study.

 

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit